Curative effect of bevacizumab combined with chemotherapy for advanced gastric cancer / 中国生化药物杂志

ABSTRACT

Objective To study the clinical efficacy of bevacizumab in combination with chemotherapy in the treatment of advanced gastric cancer. Methods 60 cases of advanced gastric cancer patients as the research object (February 2016 to January 2017), (random draw, serial number and other treatment methods) 60 cases of advanced lung cancer patients were divided into two groups (experimental group and control group, 30caes). The control group received routine chemotherapy treatment, the experimental group on the basis of 75 mg / kg bevacizumab, two groups of patients treated for 42 days. Comparative analysis of two groups of patients with quality of life and short-term efficacy and other clinical indicators. Results The quality of life score of the control group was (60.30±9.20), significantly lower than that of the experimental group, and the score was (76.88±10.90) points, with statistical difference (P<0.05). In the experimental group, 3 cases were deteriorated, and 7 cases were stable. In the control group, 6 cases were worsened, and 12 cases were stable. Available experimental treatment group total effective number of cases to 20 cases, effective rate was 66.7%, the control group was 40.0%, two groups of patients with lung cancer during treatment there were no serious adverse reactions, the incidence rate of no significant difference. Conclusions The clinical curative effect of bevacizumab combined with chemical drugs in the treatment of advanced gastric cancer is ideal, high safety, can improve the quality of life of patients in a large extent, improve the clinical symptoms, has clinical significance.